Article Information
History
- April 6, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Sammy Huygens, MD*,1,
- Bas Oude Munnink, PhD*,2,
- Arvind Gharbharan, MD1,
- Marion Koopmans, MVD PhD*,2 and
- Bart Rijnders, MD PhD*,1,†
- 1Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
- 2Department of Viroscience, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
- ↵†Corresponding author:
Bart J.A. Rijnders, b.rijnders{at}erasmusmc.nl, Dr. Molewaterplein 40 3015 GD, Rotterdam, The Netherlands, Tel: +31 10 703 35 10
↵* Contributed equally
Posted April 06, 2022.
High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant
